The committee will discuss new drug application (NDA) 214697, for epinephrine nasal spray, submitted by ARS Pharmaceuticals Inc., for the proposed indication of emergency treatment of allergic reactions (Type I) including anaphylaxis in adults and children ≥ 30 kg.
Links to Meeting Information and Materials: [ Ссылка ]
![](https://i.ytimg.com/vi/IoMiKoY4rso/maxresdefault.jpg)